openPR Logo

Press Releases from Austrianova (8 total)

Austrianova and ProAgni sign a licensing and manufacturing agreement for novel, …

Austrianova and ProAgni announced today the signing of a licensing and manufacturing agreement that foresees an intensification of joint activities between the two companies in the area of development and commercialization of shelf stable probiotic additives for cattle feed as well as for other farm animals. Austrianova, a Singaporean biotech company, has developed its patented Bac-in-a-Box® technology specifically to efficiently protect bacteria from stomach acid as well as to allow

Austrianova and San Raffaele University & Research Hospital announce the initiat …

The group of Dr. Matteo Bellone, group leader Cellular immunology Unit at San Raffaele University & Research Hospital, has shown that Prevotella melaninogenica, a commensal bacterium of the human gastrointestinal microbiota, can protect against the progression of relatively benign asymptomatic multiple myeloma to the aggressive form of the disease. Delivery of Prevotella melaninogenica in preclinical animal models prevents this progression but large doses of the bacteria are needed since they

Austrianova secures Investment from Checkmate Capital

SINGAPORE, March 02, 2023 (GLOBE NEWSWIRE) -- SG Austria ("Austrianova"), a leading provider of cell biological products and services, today announced that Checkmate Capital Group ("Checkmate Capital"), a multi-family investment and advisory group based in Pasadena, California, has made a preferred equity investment in SG Austria, the parent company of Austrianova. SG Austria, with its Austrianova Singapore and Austrianova Thailand subsidiaries, has developed the Cell-in-a-Box® and Bac-in-a-Box® platforms, which use protective

Austrianova focuses relentlessly on excellence

SINGAPORE, April 21st, 2022 Austrianova (the SG Austria group, Austrianova Singapore and Austrianova Thailand) is pleased to announce that it has been awarded ISO 9001:2015 certification for the production of encapsulated and non-encapsulated cells its facility in Thailand. ISO 9001:2015 is an internationally recognized standard that ensures that products and services meet the needs of customers through an effective quality management system. ISO 9001:2015 is in addition to the company's Good

Austrianova Secures Significant Investment from Real Tech Fund

Austrianova (the SG Austria group, Austrianova Singapore and Austrianova Thailand) is pleased and honoured to announce that, after extensive due diligence, Real Tech Fund (managed by Real Tech Holdings, Japan) has invested an undisclosed seven figure amount in Austrianova via its Real Tech Global Fund 1 to accelerate Austrianova’s growth. Real Tech Fund is a venture capital firm that invests specifically in innovative deep-technology startups mainly in Japan and Southeast

Complete protection of probiotics from destruction by stomach acid using Bac-in- …

Austrianova announced today that a key publication on the ability of its patented technology, Bac-in-a-Box, to completely protect probiotics from acidic conditions found in the stomach has been published in the well respected journal “Microbial Cell Factories” Stomach acid is nature’s way of ensuring that any microbes in food are killed before they reach the intestines. In the same way, stomach acid is also a formidable barrier to

Austrianova files Drug Master File with FDA

S.E. Asian company, Austrianova, headquartered in Singapore, announced today that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). This DMF provides all confidential and detailed information covering the production of Cell-in-a-Box® encapsulated cell products based on encapsulated HEK293 cells and derivatives. This includes CypCaps™, the encapsulated cell product that its’ partner and client PharmaCyte Biotech Inc., is about to use in

Cells for Cells and Austrianova announce publication on novel method to produce …

Austrianova and Cells for Cells have just jointly published a ground breaking, peer reviewed, scientific publication on a novel, cost and time-saving method to generate extra-cellular vesicles (EVs) from encapsulated Mesenchymal Stem Cells (MSCs). These EVs are known to mediate many of the therapeutic effects of stem cells. The authors show that Austrianova's proprietary Cell-in-a-Box encapsulation technology can be used to produce and deliver EVs from encapsulated MSC's, as demonstrated using

Go To Page:   1 2 3 4 5 6 7 8 9 10